COMPLERA
Peakemtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate
NDAORALTABLETPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
Priority Review
COMPLERA (emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate) by Gilead Sciences is nucleoside reverse transcriptase inhibitors [moa]. Approved for human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc]. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPLERA is a fixed-dose combination tablet containing emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate, approved by the FDA in August 2011. It is indicated for the treatment of HIV-1 infection and works through nucleoside reverse transcriptase inhibition to suppress viral replication. The product is currently in its peak commercial lifecycle stage and represents a once-daily oral treatment option for HIV management.
$0.0BPart D
6.7 years to LOEMechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B
Started Oct 2015
572 enrolled
Chronic Hepatitis B
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Started Oct 2012
33 enrolled
HIV-1 Infection
Career Relevance
COMPLERA supports roles in field sales, brand management, and clinical affairs, though diminishing market share limits recruitment activity. Current linked job count is zero, reflecting the product's mature and declining position relative to competitive alternatives. Professionals focused on this product require expertise in HIV treatment guidelines, formulary management, and competitive differentiation strategies, particularly around safety profile comparisons with newer agents.
Worked on COMPLERA at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.